RU2223760C2 - Способы профилактики и лечения, применение усилителей чувствительности к инсулину - Google Patents

Способы профилактики и лечения, применение усилителей чувствительности к инсулину Download PDF

Info

Publication number
RU2223760C2
RU2223760C2 RU2002104459/14K RU2002104459K RU2223760C2 RU 2223760 C2 RU2223760 C2 RU 2223760C2 RU 2002104459/14 K RU2002104459/14 K RU 2002104459/14K RU 2002104459 K RU2002104459 K RU 2002104459K RU 2223760 C2 RU2223760 C2 RU 2223760C2
Authority
RU
Russia
Prior art keywords
group
formula
enhancer
inhibitor
mammal
Prior art date
Application number
RU2002104459/14K
Other languages
English (en)
Inventor
Хитоси ИКЕДА (JP)
Хитоси ИКЕДА
Такаси СОХДА (JP)
Такаси СОХДА
Хироюки ОДАКА (JP)
Хироюки ОДАКА
Original Assignee
Такеда Кемикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15563926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2223760(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Кемикал Индастриз, Лтд. filed Critical Такеда Кемикал Индастриз, Лтд.
Application granted granted Critical
Publication of RU2223760C2 publication Critical patent/RU2223760C2/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Изобретение относится к медицине, в честности к эндокринологии, и касается лечения сахарного диабета и осложнений, связанных с диабетом. Для этого предлагают вводить препарат из группы усилителей чувствительности к инсулину, исключая троглитазон, в сочетании с препаратом из группы усилителей секреции инсулина, а также выбранном из ингибиторов альфа-глюкозидазы, ингибиторов альфа-редуктазы, бигуанидов, статиновых соединений, ингибиторов синтеза сквалена, фибратных соединений, усилителей катаболизма ЛНП и ингибиторов АПФ. Сочетания этих препаратов вводят также в виде смеси. Указанные сочетания, помимо гипогликемического эффекта, обеспечивают снижение веса, концентрации триглицеридов в плазме крови, неожиданно высокую активность в отношении снижения концентрации глюкозы в крови при сохранении дозы усилителя чувствительности к инсулину. 2 с. и 10 з.п. ф-лы, 5 табл.

Description

Текст описания в факсимильном виде (см. графическую часть)т

Claims (12)

1. Способ профилактики или лечения диабета или связанных с ним осложнений у нуждающегося в этом млекопитающего, отличающийся тем, что он включает введение указанному млекопитающему усилителя чувствительности к инсулину (исключая троглитазон) в сочетании с по меньшей мере одним членом из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозоредуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма липопротеинов низкой плотности (ЛНП) и ингибитор ангиотензинпревращающего фермента.
2. Способ по п.1, отличающийся тем, что усилитель чувствительности к инсулину представляет собой соединение, формулы
Figure 00000045
где R представляет собой возможно замещенную углеводородную или гетероциклическую группу;
Y представляет собой группу формулы -СО-, -СН(ОН)- или -NR3- (где R3 представляет собой возможно замещенную алкильную группу);
m = 0 или 1;
n = 0, 1 или 2;
Х представляет собой СН или N;
А представляет собой связь или С1-7 двухвалентную алифатическую углеводородную группу;
Q представляет собой атом кислорода или серы;
R1 представляет собой атом водорода или алкильную группу;
кольцо Е может иметь от 1 до 4 заместителей, причем заместители могут быть соединены с R1 с образованием кольца;
L и М соответственно представляют собой атом водорода или L и М могут быть соединены друг с другом с образованием связи,
или его фармакологически приемлемую соль.
3. Способ по п.2, отличающийся тем, что соединение, представленное формулой (I), представляет собой пиоглитазон.
4. Способ по п.2, отличающийся тем, что соединение, представленное формулой (I), представляет собой BRL-49653.
5. Способ по любому из пп.1 и 2, отличающийся тем, что усилитель чувствительности к инсулину смешан с по меньшей мере одним членом из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозоредуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма ЛНП и ингибитор ангиотензинпревращающего фермента с образованием смеси и данную смесь вводят млекопитающему.
6. Способ по любому из пп.1 и 2, отличающийся тем, что усилитель чувствительности к инсулину (исключая троглитазон) и по меньшей мере один член из группы, включающей ингибитор альфа-глюкозидазы, ингибитор альдозо-редуктазы, бигуанид, статиновое соединение, ингибитор синтеза сквалена, фибратное соединение, усилитель катаболизма ЛНП и ингибитор ангиотензинпревращающего фермента, не смешивают вместе, а вводят млекопитающему независимо.
7. Способ профилактики или лечения диабета или связанных с ним осложнений у нуждающегося в этом млекопитающего, отличающийся тем, что он включает введение указанному млекопитающему соединения, представленного формулой
Figure 00000046
где R` представляет собой возможно замещенную углеводородную или гетероциклическую группу;
Y представляет собой группу формулы -СО-, -СН(ОН)- или -NR3- (где R3 представляет собой возможно замещенную алкильную группу);
m = 0 или 1;
n = 0, 1 или 2;
Х представляет собой СН или N;
А представляет собой связь или С1-7 двухвалентную алифатическую углеводородную группу;
Q представляет собой атом кислорода или серы;
R1 представляет собой атом водорода или алкильную группу;
кольцо Е может иметь от 1 до 4 заместителей, причем заместители могут быть объединены с R1 с образованием кольца;
L и М соответственно представляют собой атом водорода или L и М могут быть обьединены друг с другом с образованием связи;
при условии, что R' не является бензопиранильной группой, когда m и n = 0, Х представляет собой СН, А представляет собой связь, Q представляет атом серы, R1, L и М представляют собой атом водорода, а кольцо Е не имеет дополнительных заместителей,
или его фармакологически приемлемую соль (исключая троглитазон) в сочетании с усилителем секреции инсулина.
8. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), представляет собой пиоглитазон.
9. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), представляет собой BRL-49653.
10. Способ по п.7, отличающийся тем, что усилитель секреции инсулина представляет собой сульфонилмочевину.
11. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), и усилитель секреции инсулина смешивают вместе с образованием смеси и смесь вводят млекопитающему.
12. Способ по п.7, отличающийся тем, что соединение, представленное формулой (II), и усилитель секреции инсулина не смешивают вместе, а вводят млекопитающему независимо.
RU2002104459/14K 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину RU2223760C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15350095 1995-06-20
JP07-153500 1995-06-20

Publications (1)

Publication Number Publication Date
RU2223760C2 true RU2223760C2 (ru) 2004-02-20

Family

ID=15563926

Family Applications (5)

Application Number Title Priority Date Filing Date
RU96111958/63A RU2323004C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция
RU2002104459/14K RU2223760C2 (ru) 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU96111958/14K RU2198682C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция
RU2002104459/63A RU2327455C2 (ru) 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU2003130978/14A RU2286148C2 (ru) 1995-06-20 2003-10-20 Способы профилактики и лечения, применение усилителей чувствительности к инсулину

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU96111958/63A RU2323004C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция

Family Applications After (3)

Application Number Title Priority Date Filing Date
RU96111958/14K RU2198682C2 (ru) 1995-06-20 1996-06-19 Фармацевтическая композиция
RU2002104459/63A RU2327455C2 (ru) 1995-06-20 1996-06-19 Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU2003130978/14A RU2286148C2 (ru) 1995-06-20 2003-10-20 Способы профилактики и лечения, применение усилителей чувствительности к инсулину

Country Status (26)

Country Link
US (44) US5952356A (ru)
EP (6) EP0749751A3 (ru)
JP (3) JP3148973B2 (ru)
KR (3) KR970000233A (ru)
CN (3) CN1289082C (ru)
AR (4) AR005641A1 (ru)
AT (2) ATE256463T1 (ru)
CA (3) CA2533845C (ru)
CY (4) CY2424B1 (ru)
CZ (2) CZ291624B6 (ru)
DE (4) DE122009000064I1 (ru)
DK (2) DK0861666T3 (ru)
ES (2) ES2212208T3 (ru)
FR (1) FR09C0055I2 (ru)
HK (2) HK1010484A1 (ru)
HU (1) HUP9601698A3 (ru)
LU (2) LU91298I2 (ru)
MX (1) MX9602399A (ru)
MY (1) MY127530A (ru)
NL (2) NL300258I2 (ru)
NO (5) NO313226B1 (ru)
PT (2) PT1174135E (ru)
RU (5) RU2323004C2 (ru)
SK (2) SK287351B6 (ru)
TW (2) TWI238064B (ru)
ZA (1) ZA965190B (ru)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
WO1997005875A2 (en) 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997037688A2 (en) * 1996-04-05 1997-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity
DK1175902T3 (da) 1996-07-15 2005-12-19 Sankyo Co Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
AU778947B2 (en) * 1997-06-18 2004-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
CZ298469B6 (cs) * 1997-06-18 2007-10-10 Smithkline Beecham Plc Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
AP1600A (en) * 1997-06-18 2006-04-28 Smithkline Beecham Plc Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
CA2294134A1 (en) * 1997-06-18 1998-12-23 Stephen Alistair Smith Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
AU783539B2 (en) * 1997-06-18 2005-11-10 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AU782419B2 (en) * 1997-07-18 2005-07-28 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
CA2306883C (en) * 1997-10-20 2007-11-27 Dainippon Pharmaceutical Co., Ltd. Fast-dissolving pharmaceutical composition comprising as-3201
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6329403B1 (en) * 1998-06-30 2001-12-11 Takeda Chemical Industries, Ltd. Pharmaceutical composition for the treatment of diabetes
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
ATE250418T1 (de) 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
ID29352A (id) 1998-10-29 2001-08-23 Univ Texas Penggunaan turunan tiazolidindion untuk mencegah kontraksi uterin dalam persalinan prematur atau laktasi
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AP1692A (en) * 1998-11-12 2006-12-12 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
BR9915285A (pt) * 1998-11-12 2001-08-07 Smithkline Beecham Plc Composição farmacêutica para liberação modificada de um sensitivador de insulina e um outro agente antidiabético
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
WO2000038666A2 (en) * 1998-12-24 2000-07-06 Metabasis Therapeutics, Inc. A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
JP4799720B2 (ja) * 1999-01-29 2011-10-26 武田薬品工業株式会社 コーティング処理を施した打錠用杵
US6787082B1 (en) * 1999-01-29 2004-09-07 Takeda Chemical Industries, Ltd. Compressing mallet with coating treatment
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
CN1329359C (zh) * 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
JP2000355550A (ja) * 1999-04-14 2000-12-26 Takeda Chem Ind Ltd ケトーシス改善剤
BR0009934A (pt) * 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
GB9910693D0 (en) * 1999-05-07 1999-07-07 Univ Liverpool A compound for use in medicine
US6214842B1 (en) * 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
CA2377246A1 (en) * 1999-06-18 2000-12-28 Ranjit C. Desai Arylthiazolidinedione and aryloxazolidinedione derivatives
EP1849475A1 (en) 1999-06-21 2007-10-31 Eli Lilly & Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
AU779730B2 (en) * 1999-06-30 2005-02-10 Amgen, Inc. Compounds for the modulation of PPARgamma activity
WO2001000579A1 (en) * 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP4719393B2 (ja) * 1999-10-06 2011-07-06 敏男 宮田 カルボニルストレス改善剤
AU1133901A (en) * 1999-10-08 2001-04-23 Novartis Ag Method of treating metabolic disorders
US6274622B1 (en) * 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
HU229352B1 (en) 1999-11-03 2013-11-28 Bristol Myers Squibb Co Medicament comprising the combination of metformin and glyburide
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6402771B1 (en) 1999-12-23 2002-06-11 Guidant Endovascular Solutions Snare
US6660021B1 (en) 1999-12-23 2003-12-09 Advanced Cardiovascular Systems, Inc. Intravascular device and system
US6575997B1 (en) 1999-12-23 2003-06-10 Endovascular Technologies, Inc. Embolic basket
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
WO2001047509A2 (en) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
US7918820B2 (en) 1999-12-30 2011-04-05 Advanced Cardiovascular Systems, Inc. Device for, and method of, blocking emboli in vessels such as blood arteries
US6695813B1 (en) 1999-12-30 2004-02-24 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
WO2001052860A2 (en) * 2000-01-24 2001-07-26 Inotek Corporation Method and composition for modulating an immune response
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US6939362B2 (en) * 2001-11-27 2005-09-06 Advanced Cardiovascular Systems, Inc. Offset proximal cage for embolic filtering devices
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6964670B1 (en) 2000-07-13 2005-11-15 Advanced Cardiovascular Systems, Inc. Embolic protection guide wire
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
CA2424060A1 (en) * 2000-10-12 2003-03-31 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
US6506203B1 (en) 2000-12-19 2003-01-14 Advanced Cardiovascular Systems, Inc. Low profile sheathless embolic protection system
EP1349531A1 (en) 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Spaced drug delivery system
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
EP1236720B1 (en) 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DE50207110D1 (de) * 2001-03-02 2006-07-20 Lichtwer Pharma Gmbh Kombinationspräparat zur behandlung des diabetes mellitus
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
ATE348100T1 (de) 2001-03-30 2007-01-15 Pfizer Prod Inc Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren.
CN1499971A (zh) * 2001-04-03 2004-05-26 ֮����ҩ��ʽ���� 芳基乙烯磺酰胺衍生物的新用途
PT1377276E (pt) * 2001-04-10 2011-12-30 Sun Pharma Advanced Res Co Ltd Composição de libertação temporizada por pulso
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US7338510B2 (en) 2001-06-29 2008-03-04 Advanced Cardiovascular Systems, Inc. Variable thickness embolic filtering devices and method of manufacturing the same
US6599307B1 (en) 2001-06-29 2003-07-29 Advanced Cardiovascular Systems, Inc. Filter device for embolic protection systems
CA2453784A1 (en) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. A core formulation
CA2453775A1 (en) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
US6592606B2 (en) 2001-08-31 2003-07-15 Advanced Cardiovascular Systems, Inc. Hinged short cage for an embolic protection device
US8262689B2 (en) 2001-09-28 2012-09-11 Advanced Cardiovascular Systems, Inc. Embolic filtering devices
CA2469228A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7241304B2 (en) 2001-12-21 2007-07-10 Advanced Cardiovascular Systems, Inc. Flexible and conformable embolic filtering devices
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
PE20040291A1 (es) * 2002-03-22 2004-07-02 Novartis Ag COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
US20050142065A1 (en) * 2002-04-26 2005-06-30 Koki Kato Screening method
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
JP2005537298A (ja) 2002-08-02 2005-12-08 ペンウェスト ファーマシューティカルズ カンパニー メトホルミンの徐放性製剤
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (ko) 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7252675B2 (en) 2002-09-30 2007-08-07 Advanced Cardiovascular, Inc. Embolic filtering devices
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040088000A1 (en) 2002-10-31 2004-05-06 Muller Paul F. Single-wire expandable cages for embolic filtering devices
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
IN192749B (ru) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
NZ541749A (en) * 2003-01-29 2009-06-26 Takeda Pharmaceutical Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US8591540B2 (en) 2003-02-27 2013-11-26 Abbott Cardiovascular Systems Inc. Embolic filtering devices
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
BRPI0409136A (pt) * 2003-04-09 2006-04-25 Japan Tobacco Inc composto heteroaromático pentacìclico e uso medicinal do mesmo
US7820158B2 (en) * 2003-04-10 2010-10-26 Surmodics, Inc. Ligand-coupled initiator polymers and methods of use
US9345671B2 (en) * 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
CA2524175C (en) * 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
JP2007502847A (ja) * 2003-05-13 2007-02-15 シントン・ベスローテン・フェンノートシャップ チアゾリジンジオン誘導体およびその化合物を製造する方法
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
BRPI0412009A (pt) * 2003-06-27 2006-08-15 Reddy Research Foundation composições compreendendo balaglitazona e outros compostos antidiabéticos
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1651251A4 (en) * 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CA2543498A1 (en) * 2003-10-27 2005-05-06 Innodia Inc. Use of hydroxylated amino acids for treating diabetes
HUE028576T2 (en) * 2003-10-31 2016-12-28 Takeda Pharmaceuticals Co Solid preparation containing pioglitazone, glimepiride and polyoxyethylene sorbitan fatty acid ester
US7892251B1 (en) 2003-11-12 2011-02-22 Advanced Cardiovascular Systems, Inc. Component for delivering and locking a medical device to a guide wire
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
US7360069B2 (en) * 2004-01-13 2008-04-15 Hewlett-Packard Development Company, L.P. Systems and methods for executing across at least one memory barrier employing speculative fills
EP1555021A1 (en) * 2004-01-16 2005-07-20 National Health Research Institutes Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
EP1716144A2 (en) * 2004-02-20 2006-11-02 Synthon B.V. Processes for making pioglitazone and compounds of the processes
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS
US7678129B1 (en) 2004-03-19 2010-03-16 Advanced Cardiovascular Systems, Inc. Locking component for an embolic filter assembly
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
CN101014360A (zh) * 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素-双胍组合物
JP2008514549A (ja) * 2004-09-14 2008-05-08 エリクシアー ファーマシューティカルズ, インコーポレイテッド 制御された炭水化物消化のための併用療法
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ppar調節剤およびそのスクリーニング方法
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US9259305B2 (en) 2005-03-31 2016-02-16 Abbott Cardiovascular Systems Inc. Guide wire locking mechanism for rapid exchange and other catheter systems
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
CN101217965B (zh) * 2005-07-07 2012-07-18 学校法人浦项工科大学校 葡萄糖吸收调节剂和用于治疗糖尿病或糖尿病并发症的方法
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
CN101227908A (zh) * 2005-07-22 2008-07-23 宝洁公司 用于减少药源性心律失常发生的组合物
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
TWI384985B (zh) 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007105730A1 (ja) * 2006-03-13 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. インスリン抵抗性改善剤
AU2007227581B2 (en) 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
CA2647258A1 (en) * 2006-03-31 2007-10-18 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
WO2007117147A1 (en) * 2006-04-11 2007-10-18 Sorbwater Technology As Method for removal of materials from a liquid stream
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
US7752724B2 (en) * 2006-06-27 2010-07-13 Lumino, Inc. Method of cutting blinds
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US20080176905A1 (en) * 2007-01-22 2008-07-24 Santiago Ini Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
BRPI0807453B8 (pt) * 2007-02-01 2021-05-25 Takeda Pharmaceuticals Co preparação sólida
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2008240158B2 (en) 2007-04-11 2014-07-10 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
EP2489730B1 (en) 2007-07-26 2015-12-30 Amgen, Inc Modified lecithin-cholesterol acyltransferase enzymes
CN101848901B (zh) * 2007-09-14 2012-11-21 新陈代谢解决方案开发公司 用于治疗高血压的噻唑烷二酮类似物
JPWO2009038107A1 (ja) * 2007-09-21 2011-01-06 キッセイ薬品工業株式会社 2型糖尿病治療用の組合せ医薬
US20100311092A1 (en) * 2007-11-30 2010-12-09 Kurland Irwin J Metabolic fuel switching biomarker
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8815508B2 (en) 2008-08-12 2014-08-26 Zinfandel Pharmaceuticals, Inc. Method of identifying disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP3398599A1 (en) 2009-03-11 2018-11-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20110038848A1 (en) * 2009-08-12 2011-02-17 Melaleuca, Inc. Dietary supplement compositions for cardiovascular health
CN102655866B (zh) 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
US8575177B2 (en) * 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
JP2013514368A (ja) * 2009-12-15 2013-04-25 メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー 神経変性疾患を処置するための、ppar温存チアゾリジンジオンおよび組み合わせ物
ES2658168T3 (es) * 2009-12-15 2018-03-08 Cirius Therapeutics, Inc. Sales de tiazolidinadiona ahorradoras de PPAR para el tratamiento de enfermedades metabólicas
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
JP2013523819A (ja) * 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
RU2526153C2 (ru) * 2010-07-15 2014-08-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료
SG191399A1 (en) 2011-01-10 2013-08-30 Zinfandel Pharmaceuticals Inc Methods and drug products for treating alzheimer's disease
HUE026715T2 (en) 2011-01-20 2016-07-28 Bionevia Pharmaceuticals Inc Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use
WO2013034174A1 (en) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
DK2771003T3 (en) 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
EP3065757A4 (en) 2013-10-09 2017-08-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
RU2572706C1 (ru) * 2014-06-30 2016-01-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
DK3253382T3 (da) 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
WO2018130679A1 (en) 2017-01-16 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
EP3807895A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood sugar with a metformin pharmaceutical composition
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
CN112869173A (zh) * 2021-01-18 2021-06-01 广州富诺营养科技有限公司 一种复合维生素矿物质制剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5728073A (en) * 1980-07-29 1982-02-15 Takeda Chem Ind Ltd Inhibitor for aldose reducing enzyme
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
WO1988006887A1 (en) 1987-03-20 1988-09-22 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
ES2137915T3 (es) 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH0466579A (ja) * 1990-07-04 1992-03-02 Yamanouchi Pharmaceut Co Ltd チアゾリジン誘導体
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2686861B2 (ja) * 1991-03-30 1997-12-08 キッセイ薬品工業株式会社 新規なベンジリデンコハク酸誘導体
DK0601001T3 (da) * 1991-08-26 1997-10-20 Upjohn Co Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre.
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
JPH07316144A (ja) * 1994-03-29 1995-12-05 Sankyo Co Ltd ジフェニルメチルピペラジン誘導体
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6001049A (en) * 1998-02-12 1999-12-14 Frey; Mark P. Light weight exercise apparatus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEFEVRE et al. Drugs. - 1992, 44, р.29-38. *
Клиническая эндокринология. Руководство для врачей/Под ред. Н.Т. Старковой. - М.: Медицина, 1991, с.236-239, 254-256. *

Also Published As

Publication number Publication date
NO2007001I1 (no) 2007-01-29
KR970000233A (ko) 1997-01-21
CA2531834A1 (en) 1996-12-21
US6121294A (en) 2000-09-19
US6251924B1 (en) 2001-06-26
US6150384A (en) 2000-11-21
US6211207B1 (en) 2001-04-03
NO20021172L (no) 1996-12-23
DE122007000002I1 (de) 2012-03-08
US6156773A (en) 2000-12-05
US6103742A (en) 2000-08-15
PT861666E (pt) 2004-05-31
US6150383A (en) 2000-11-21
ATE438397T1 (de) 2009-08-15
CA2533845A1 (en) 1996-12-21
DE69637988D1 (de) 2009-09-17
SK287351B6 (sk) 2010-08-09
US20020002186A1 (en) 2002-01-03
US6329404B1 (en) 2001-12-11
RU2327455C2 (ru) 2008-06-27
EP0861666A3 (en) 1999-02-10
ES2327383T3 (es) 2009-10-29
US6323225B1 (en) 2001-11-27
US6225326B1 (en) 2001-05-01
EP1174135A3 (en) 2002-06-19
NO317341B1 (no) 2004-10-11
CN1145783A (zh) 1997-03-26
ES2327383T5 (es) 2017-03-13
US6169100B1 (en) 2001-01-02
US6211205B1 (en) 2001-04-03
RU2003130978A (ru) 2005-04-20
CN1289082C (zh) 2006-12-13
US20070203198A1 (en) 2007-08-30
CY2009018I1 (el) 2010-07-28
NO962606D0 (no) 1996-06-19
SK79496A3 (en) 1997-01-08
US7144900B2 (en) 2006-12-05
KR20070081135A (ko) 2007-08-16
AR061195A2 (es) 2008-08-13
DE122009000064I1 (de) 2011-12-01
US20110034518A1 (en) 2011-02-10
EP1174135B9 (en) 2009-12-16
US6166042A (en) 2000-12-26
US6166043A (en) 2000-12-26
US6080765A (en) 2000-06-27
JP2007191494A (ja) 2007-08-02
FR09C0055I1 (ru) 2009-04-12
SK287287B6 (sk) 2010-05-07
US6174904B1 (en) 2001-01-16
US6288090B1 (en) 2001-09-11
DE122007000002I2 (de) 2012-03-08
PT1174135E (pt) 2009-08-31
US6133295A (en) 2000-10-17
TW438587B (en) 2001-06-07
CZ291624B6 (cs) 2003-04-16
EP2289556A3 (en) 2011-03-09
NO313226B1 (no) 2002-09-02
US6121295A (en) 2000-09-19
CN1212117C (zh) 2005-07-27
ATE256463T1 (de) 2004-01-15
CA2179584A1 (en) 1996-12-21
US20030216443A1 (en) 2003-11-20
CN1530106A (zh) 2004-09-22
US7842706B2 (en) 2010-11-30
US6214848B1 (en) 2001-04-10
US6271243B1 (en) 2001-08-07
DK0861666T3 (da) 2004-03-08
EP1174135B1 (en) 2009-08-05
NL300432I2 (en) 2010-04-01
HK1041203A1 (en) 2002-07-05
NO2007007I1 (no) 2007-06-18
CA2533845C (en) 2012-10-09
US6239153B1 (en) 2001-05-29
US6232330B1 (en) 2001-05-15
US20040266830A1 (en) 2004-12-30
DE69631157D1 (de) 2004-01-29
US5965584A (en) 1999-10-12
JP3148973B2 (ja) 2001-03-26
EP1174135A2 (en) 2002-01-23
HK1041203B (zh) 2009-09-25
US6274605B1 (en) 2001-08-14
HU9601698D0 (en) 1996-08-28
CY2007001I1 (el) 2009-11-04
HUP9601698A3 (en) 2000-09-28
US20020128289A1 (en) 2002-09-12
NO20004345L (no) 1996-12-23
US6211206B1 (en) 2001-04-03
CY2009018I2 (el) 2010-07-28
NO2007007I2 (no) 2009-10-05
DK1174135T3 (da) 2009-12-07
NL300432I1 (en) 2010-03-01
US6599923B2 (en) 2003-07-29
CN1530105A (zh) 2004-09-22
NL300258I1 (nl) 2007-04-02
US6303640B1 (en) 2001-10-16
US20020042434A1 (en) 2002-04-11
CA2179584C (en) 2007-04-24
NL300258I2 (nl) 2007-05-01
RU2323004C2 (ru) 2008-04-27
EP1764110A1 (en) 2007-03-21
NO20004345D0 (no) 2000-09-01
US6218409B1 (en) 2001-04-17
US6172090B1 (en) 2001-01-09
HK1010484A1 (en) 1999-06-25
JP4809806B2 (ja) 2011-11-09
EP2289556A2 (en) 2011-03-02
US7538125B2 (en) 2009-05-26
CY2608B2 (en) 2010-04-28
MX9602399A (es) 1997-02-28
AR065389A2 (es) 2009-06-03
DE69631157T2 (de) 2004-09-09
AR091289A2 (es) 2015-01-28
NO962606L (no) 1996-12-23
US5952356A (en) 1999-09-14
EP2292268A1 (en) 2011-03-09
CZ181196A3 (en) 1997-01-15
AU5603496A (en) 1997-01-09
EP0861666A2 (en) 1998-09-02
ZA965190B (en) 1997-12-19
US6169099B1 (en) 2001-01-02
KR20080005162A (ko) 2008-01-10
RU2286148C2 (ru) 2006-10-27
AR005641A1 (es) 1999-07-14
US20090246232A1 (en) 2009-10-01
FR09C0055I2 (fr) 2010-06-11
EP0861666B1 (en) 2003-12-17
US20020123512A1 (en) 2002-09-05
JPH0967271A (ja) 1997-03-11
CY2007001I2 (el) 2009-11-04
RU2198682C2 (ru) 2003-02-20
JP3973280B2 (ja) 2007-09-12
US6277869B1 (en) 2001-08-21
CZ292093B6 (cs) 2003-07-16
NO20021172D0 (no) 2002-03-08
LU91606I2 (fr) 2009-11-09
TWI238064B (en) 2005-08-21
US6133293A (en) 2000-10-17
CA2531834C (en) 2006-12-05
US6384062B1 (en) 2002-05-07
ES2212208T3 (es) 2004-07-16
MY127530A (en) 2006-12-29
US6172089B1 (en) 2001-01-09
NO314065B1 (no) 2003-01-27
NO2007001I2 (no) 2011-03-14
EP1174135B2 (en) 2016-09-14
HUP9601698A2 (hu) 1997-05-28
JPH10167986A (ja) 1998-06-23
AU723097B2 (en) 2000-08-17
EP0749751A3 (en) 1997-04-16
CY2424B1 (en) 2004-11-12
EP0749751A2 (en) 1996-12-27
US20050054685A1 (en) 2005-03-10
US6911459B2 (en) 2005-06-28
LU91298I2 (fr) 2007-02-20

Similar Documents

Publication Publication Date Title
RU2223760C2 (ru) Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU2002104459A (ru) Способы профилактики и лечения, применение усилителей чувствительности к инсулину
RU96111958A (ru) Фармацевтическая композиция
CA1331020C (en) Medicament with improved penetration of the tissue membrane
RU2227800C2 (ru) Новые эффекторы дипептидилпептидазы iv
JP4875491B2 (ja) メトホルミンとスタチンとの組み合わせを含む医薬組成物
AU2006222060B2 (en) Roflumilast for the treatment of diabetes mellitus
RU2001118826A (ru) N-замещенные 2-цианопирролидины
RU95118725A (ru) Производные оксазолидиндиона, их получение и фармацевтическая композиция
RU2006143666A (ru) Фармацевтические композиции в виде раствора, содержащие 17-aag
RU2009102515A (ru) Конденсированные циклические соединения
CN1186495A (zh) 降低活体内氧化氮水平的方法及其可用的组合物
CN1155409C (zh) 用于预防和治疗动脉硬化的药物组合物
JP2007528886A (ja) 肥満の治療又は予防用のメトホルミン及びオルリスタットの使用
RU2004109586A (ru) Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов
CA2377661A1 (en) Use of fatty acid derivative for the treatment of external secretion disorders
DE69405425D1 (de) Oxazolidinedione-Derivate, ihre Herstellung und ihre Verwendung zur Hemmung Zucker und Lipid in Blut
WO2018148206A1 (en) Treatment of diabetes and associated metabolic conditions with epigenetic modulators
AU601326B2 (en) 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
BR0311834A (pt) Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
AU637745B2 (en) Use of tenidap to inhibit the activity of myeloperoxidase
CA2445651A1 (en) Cathartic composition comprising halogenated prostaglandin derivatives
CA1313139C (en) D1-5-[(2-benzyl-3,4-dihydro-2h-benzopyran-6-yl)methyl] thiazolidine-2,4-dione as an anti-atherosclerosis agent
NZ312571A (en) Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein
EP0132994A1 (en) Compounds for lowering lipid levels

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MF42 Invention patent partially invalidated

Effective date: 20071205